Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

David A. Hyman, MD, JD, on Inclusive Shared Savings

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Sep

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

David A. Hyman, MD, JD, on Inclusive Shared Savings

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

What Constitutes Clinical Expertise in an AI-Enabled Era

NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease

FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer

FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia

FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera